A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
about
Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumorPresent Advances and Future Perspectives of Molecular Targeted Therapy for OsteosarcomaVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationOsteosarcoma: Current Treatment and a Collaborative Pathway to SuccessPotential approaches to the treatment of Ewing's sarcomaReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersImatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine modelsExploring targeted therapy of osteosarcoma using proteomics dataPlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single instituteDocetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult populationCardiovascular disease in adult survivors of childhood cancer.Targeting the PDGF signaling pathway in tumor treatmentThe treatment of pediatric chronic myelogenous leukemia in the imatinib eraDermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Targeted therapies for advanced Ewing sarcoma family of tumors.Improving access to novel agents for childhood leukemia.PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.How I treat childhood CML.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentTargeted therapy in Ewing sarcoma.Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardMolecular profiling of childhood cancer: Biomarkers and novel therapiesThe biology of ewing sarcomaSuccinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Cell survival signaling in neuroblastoma.Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.Molecular characterization of pediatric gastrointestinal stromal tumors.Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinomaNew anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.Novel targeted therapies in the treatment of soft-tissue sarcomas.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
P2860
Q21342824-6A11A480-591D-4CAE-9A9A-B0E8B5694243Q26750631-D941E798-5808-4AC6-A277-469F2FCBDEB1Q26781833-8339FBB3-30CE-454E-89F2-953A43AD8DB2Q26797555-FD6F89B1-58BA-419E-8DB8-ECFEEADFAC0DQ28072744-79A1922D-2B49-4AC1-A8D2-0674D458D05CQ28082793-EC2E968A-9E51-49A0-B1F3-955E9CBC034EQ28540520-CDEBD6D9-EE5E-4340-BA6C-D6E0D5243C54Q28817274-C7B9892B-9165-416A-9BD0-AC6B1C94D8B2Q30250273-8005A4DD-4BDB-4F1B-A625-B78D9109AEACQ33418020-487F0E2F-DF20-48BD-BE3C-24E8BE7A11C1Q33439510-D6860DB3-56DE-4F43-9D45-8059BDAB6099Q33654872-BE764CED-FC4F-4C0D-8531-2F66C585354FQ34042984-43EBF7FF-6FF8-42CA-A4A3-3663843B8E20Q34393461-47BCC03E-755D-403C-A928-14729680D8BBQ35062049-E04FC165-6DB5-480C-B0DE-30C87A9464FAQ35224485-A1CFAB1C-4F2E-433C-8CE9-261139969716Q35562745-BEBE85E0-9647-49F0-9FDB-22EA5BC1D50CQ35589492-8D72FFBA-F224-4857-A223-B3EFFEE694B9Q35688742-64D309FE-6BC6-4085-AEAB-295AABB979ACQ35763861-454AFEEE-6F63-48F3-A9BF-D8AA968DB3C6Q35802202-50E7FC1C-6822-4202-A709-FF29723EF0EBQ35894540-54AFC53E-BC85-4A0C-8CE8-E785C8D5D4CEQ35904214-486D545E-6B4B-4A9E-8F1A-2EBCB000A8F2Q35957998-CAF66F84-1918-4C2C-BC2C-6AD78C5C1707Q35958048-075D98B2-1F4C-4AF6-8CF5-63646726E7FDQ36011879-F4E5DB11-1E83-4551-8FCD-9DBE5C3A338EQ36072962-40FC5AC9-48EC-4178-92E9-FFF6F21DC611Q36250783-EB1F67C3-30FA-4C41-8DD4-EA471C2E4960Q36546372-1289ECAF-0C24-46E1-A85C-54CF8522BC50Q36850606-7E6103D8-C401-44DE-8441-5D0C82AE6B13Q36888962-E4781080-6B9F-4352-816A-11595963A0C1Q37010166-29A38036-548F-4097-96C1-0BDFAC828890Q37109503-AB2DEFA4-DF76-4BE5-9A2E-793B6D85B3F6Q37247100-56F7AF31-8A4B-4F28-ADF1-F4C6879FA8E2Q37301320-2B9AFB9D-9C7F-47F8-8384-F7120F970B19Q37481150-15C073AA-61F9-42D1-87CC-CEDF36AA355AQ37694240-3521FBF5-76F4-45F0-81F1-5353A5A59421Q37752435-7F500D17-8E31-4E8B-B808-710D0BFA8E8CQ37782097-C0C770B1-0DC1-4363-A055-7F7A8504E25EQ37834445-FACF8D39-A24C-482B-B0AC-B65B64F645C0
P2860
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A phase II study of imatinib m ...... ildren's Oncology Group study.
@en
A phase II study of imatinib m ...... ildren's Oncology Group study.
@nl
type
label
A phase II study of imatinib m ...... ildren's Oncology Group study.
@en
A phase II study of imatinib m ...... ildren's Oncology Group study.
@nl
prefLabel
A phase II study of imatinib m ...... ildren's Oncology Group study.
@en
A phase II study of imatinib m ...... ildren's Oncology Group study.
@nl
P2093
P356
P1476
A phase II study of imatinib m ...... ildren's Oncology Group study.
@en
P2093
Alberto Pappo
Mark Krailo
Mark L Bernstein
Mason Bond
Peter C Adamson
P304
P356
10.1002/PBC.21132
P577
2008-02-01T00:00:00Z